Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings in Brief: Biomagnetic Technologies, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Biomagnetic Technologies, Inc.: Sale of 5.5 mil. shares of common stock to foreign investors raises $2.8 mil. Dassesta International was the largest investor, acquring 4 mil. shares for $2 mil. The proceeds are intended primarily for debt repayment and working capital. The San Diego-based magnetic source imaging equipment firm "is currently in the process of seeking additional substantial equity capital from foreign investors to continue its operations beyond the end of February 1998, at which time its existing cash resources may be exhausted, precluding the company's ability to continue operations," VP-Finance Henry Bergman explains. Fiscal 1997 (ended Sept. 30) results include sales of $10.6 mil. versus $733,000 last year and a net loss of $5.2 mil. compared to $15.6 mil. in the prior year. The results reflect the fact that shipments of the firm's Magnes 2500 whole head system, "which had been delayed from fiscal year 1996, have been installed and accepted in Europe, Japan and the United States," the firm states...

You may also be interested in...

Moderna Files COVID-19 Vaccine After Second Impressive Read-Out

Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.

Sanofi's Dupixent Cleared For Children With Atopic Dermatitis In EU

The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.

Coronavirus Notebook: UK On Cusp Of First Vaccine Approval, Moderna To File mRNA-1273 in US & EU

Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts